66.8 F
Elizabeth City
Tuesday, May 11, 2021

Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses

Must read

The main composite renal endpoint from VERTIS CV didn’t show significant benefit from ertugliflozin over placebo, but in additional analyses showed kidney benefits from this SGLT2 inhibitor. Medscape Medical News
Read More

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest article